<DOC>
	<DOCNO>NCT00823342</DOCNO>
	<brief_summary>For chronic HBV infection , optimal pharmacological agent promote recovery chronic HBV infection would one inhibit HBV DNA polymerase , combine clearence liver cccDNA block HBV reactivation circulate viral burden eliminate therapy . The activity clevudine cccDNA combination potent antiviral activity HBV polymerase make optimal agent combination tenofovir protocol .</brief_summary>
	<brief_title>ANRS HB 05 Multicenter Study Evaluating Efficacy Safety Clevudine Monotherapy Versus Tenofovir Monotherapy Versus Combination Therapy Clevudine Tenofovir 96 Weeks HBeAg Negative Patients With Chronic Hepatitis B , naïve Anti-VHB Therapy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Clevudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Male female patient 18 year age Chronic hepatitis B , HBs Agpositive 6 month , anti HBs negative Patients HBeAg negative chronic hepatitis B ( CHB ) antiHBe positive screen Patients naïve antiHBV nucleoside nucleotide experimental nucleoside/nucleotide analog HBV Serum HBVDNA quantifiable 2000 IU/mL screen ALT 1.25 ULN 10 ULN Liver biopsy ( baseline within prior 6 month ) evidence chronic hepatic inflammatory injury ( Metavir Activity score 1 ; Knodell necroinflammatory score 3 , Ishak score 1 ) Cirrhosis bridge fibrosis liver biopsy Subjects receive form alpha interferon past 6 month prior first administration randomize treatment Any systemic antiviral , antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) 6 month prior first dose randomize treatment study ( except 10 day acyclovir herpetic lesion , prednisone 10 mg/days 10 day 1 month ) Women ongoing pregnancy breast feed Positive test screen antiHAV IgM Ab , antiHIV Ab , antiHCV Ab , HCV RNA , antiHDV Ab History evidence medical condition associate chronic liver disease HBV ( e.g. , hemochromatosis , autoimmune hepatitis , metabolic liver disease include Wilson 's disease alpha1antitrypsin deficiency , alcoholic liver disease , toxin exposure , toxic thalassemia , NASH ) History evidence bleed esophageal varix clinical condition consistent decompensated liver disease ( define one follow criterion meet : serum albumin 3.5 g/L , prothrombin time 4 second prolonged , serum bilirubin 34 µmol/L , history encephalopathy , history ascites ) Neutrophil count 1200 cells/mm3 platelet count 90,000 cells/mm3 screen Serum creatinine level 130µmol/l calculated creatinine clearance 70 ml/min ( CockcroftGault ) Evidence history tubular nephropathy , Fanconi syndrom hypophosphoremia . Evidence drug abuse ( include excessive alcohol consumption ) within one year study entry History severe seizure disorder current anticonvulsant use History immunologically mediate disease ( e.g. , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis , rheumatoid arthritis etc . ) History major organ transplantation exist functional graft History evidence severe illness condition would make patient , opinion investigator , unsuitable study Evidence active suspect cancer history malignancy risk recurrence 20 % within 2 year Patients value alphafetoprotein 100 ng/mL exclude , unless stability ( le 10 % increase ) document least previous 3 month Patients include another trial within 8 week prior screen Inability unwillingness provide inform consent abide requirement study Reassessments : If patient fail meet inclusion /exclusion criterion reason think reversible , patient may reassess entry two additional occasion . If parameter range inclusion ALT 10 x ULN , patient reassess 4 week date correspond value 10 x ULN .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>HBe , Hepatitis , Vireda ( TENOFOVIR , CLEVUDINE ) , HBV , HBe Ag negative</keyword>
</DOC>